Thursday, 02 April 2020

Drug Discovery News

  • Openvas by Daiichi Sankyo launched in Mexico

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 11 Jun, 2012

    Singapore: Japan-based Daiichi Sankyo has launched antihypertensive franchise olmesartan medoxomil in Mexico under the name Openvas. It has also launched Openvas Co, a combination preparati...Read more

  • Osteoporosis is an emerging crisis in APAC: Report

    Drug Discovery |  Analysis | By BioSpectrum Bureau  | 0 Comment | 13 Dec, 2013

    Singapore: A new report, launched by the International Osteoporosis Foundation (IOF), shows that osteoporosis is a looming crisis throughout the Asia Pacific, with the number of fracture su...Read more

  • Genting to acquire 20% equity stake in TauRx

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 20 Nov, 2012

    Singapore: Singapore-based TauRx Pharmaceuticals has received equity investment of $31.5 million from Genting Management Singapore (GMS), a wholly owned subsidiary of Genting Berhad. The am...Read more

  • Nanotherapeutics seeks GE help to step up development

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 24 Jan, 2014

    Singapore: Biopharmaceutical company Nanotherapeutics has selected GE Healthcare Life Sciences' FlexFactory biomanufacturing platform to perform a central role in its Advanced Development a...Read more

  • Steroid pioneer gets Heritage Foundation, BIO award

    Drug Discovery |  Influencers | By BioSpectrum Bureau  | 0 Comment | 22 Apr, 2013

    Singapore: Chemical Heritage Foundation (CHF) and Biotechnology Industry Organization (BIO) have selected Mexican steroid scientist, Dr George Rosenkranz, as the winner of the 2013 Biotechn...Read more

  • Austrianova starts cell bank for cancer therapy

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 21 Mar, 2013

    Singapore: Austrianova Singapore has established a research cell bank, the first step towards late-phase clinical trials in patients with advanced inoperable pancreatic cancer, as well as a...Read more

  • Takeda, Dainippon to market schizophrenia drug

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 13 Aug, 2013

    Singapore: Japanese companies Dainippon Sumitomo Pharma and Takeda Pharmaceutical have obtained approval for marketing authorization by Swissmedic for atypical antipsychotic medication lura...Read more

  • Astellas to pay $300 mn for cancer drug conjugates

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 05 Apr, 2013

    Singapore: Japan's Astellas Pharma has collaborated with US-based Ambrx for the discovery and development of novel antibody drug conjugates (ADCs), which allow for the targeted delivery of ...Read more

  • Jubilant, Janssen expand drug discovery alliance

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 21 Feb, 2014

    Singapore: Jubilant Biosys, a subsidiary of Bangalore-based Jubilant Life Sciences, has expanded its drug discovery alliance with Janssen Pharmaceutica, that was forged initially in the yea...Read more

  • Patrys' 2nd group concludes treatment in Germany

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 10 Apr, 2013

    Singapore: Patrys completed initial treatment of second group of three patients in its phase I/IIa PAT-SM6 multiple myeloma trial. The group was treated in the Department of Haematology an...Read more

  • AstraZeneca biologics R&D arm acquires Amplimmune

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 27 Aug, 2013

    Singapore: AstraZeneca's global biologics R&D arm, MedImmune, plans to acquire Amplimmune, which is a US-based biologics company focused on developing novel therapeutics in cancer immun...Read more

  • Biostar, Shaanxi Uni to co-develop liver cancer drug

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 07 Mar, 2014

    Singapore: Biostar Pharmaceuticals, a China-based manufacturer and marketer of pharmaceutical and health supplement products, has signed a letter of intent with Research Institute of Pharma...Read more

  • Otsuka schizophrenia relapse gets FDA nod

    Drug Discovery |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 01 Mar, 2013

    Singapore: Japan-based Otsuka Pharmaceutical and H Lundbeck have received US FDA approval for Abilify Maintena (aripiprazole) extended-release injectable suspension, an intramuscular (IM) d...Read more

  • Novogen to develop new class of cancer drugs

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 09 Oct, 2013

    Singapore: Australia-based Novogen has acquired a novel drug technology that will be developed as a potentially major class of cancer drugs known as anti-tropomyosins (anti-Tms), joining th...Read more

  • FDA issues complete response letter for XARELTO

    Drug Discovery |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 22 Jun, 2012

    Singapore: US Food and Drug Administration (FDA) have issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of t...Read more

  • Sanofi to develop novel drugs for drug-resistant TB

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 25 Sep, 2012

    Singapore: Sanofi and the Global Alliance for TB Drug Development (TB Alliance) entered a research collaboration to accelerate the discovery and development of novel compounds against tuber...Read more

  • Lupin aims high with a strong R&D focus

    Drug Discovery |  Analysis | By BioSpectrum Bureau  | 0 Comment | 18 Jun, 2012

    Lupin Pharmaceutical, which aims to be the best transnational pharmaceutical company in the world, stroked 10.64 percent growth in its sales and marked a successful period in 2011. Lupin ac...Read more

  • Phosphagenics appoints three new non-executive directors

    Drug Discovery |  Influencers | By BioSpectrum Bureau  | 0 Comment | 04 Mar, 2014

    Singapore: Australian drug delivery technology company Phosphagenics has appointed biotech industry veterans Mr Lawrence Gozlan, Mr Nathan Drona and Dr Geert Cauwenbergh as non-executive di...Read more